Fenge Li

AUG 19, 2026 · JOURNAL ARTICLE

Genetic Engineering of Tumor‐Infiltrating Lymphocytes ( TIL ) via a T‐Editor Platform to Enhance Anti‐Tumor Activity

Cancer Science

Early-stage mechanistic work demonstrating proof-of-concept for a gene-editing platform in preclinical and PDX models, without human clinical efficacy data or direct comparison to standard TIL therapy.

AUG 11, 2026 · JOURNAL ARTICLE

T cell receptor repertoire dynamics and newly identified functional regulators of autologous tumor-infiltrating lymphocyte therapy in advanced solid tumors

Journal of Translational Medicine

Phase 1 investigator-initiated trial in 12 patients with heterogeneous solid tumors, showing feasibility and a 33.3% response rate, but underpowered for efficacy claims and mechanistic findings rely on uncontrolled in vitro and in vivo knockout experiments.